115 related articles for article (PubMed ID: 26561054)
1. Dendritic Cells in Esophageal Adenocarcinoma: The Currently Available Information and Possibilities to use Dendritic Cells for Immunotherapeutic Approaches.
Chistiakov DA; Orekhov AN; Bobryshev YV
Curr Pharm Des; 2016; 22(3):307-11. PubMed ID: 26561054
[TBL] [Abstract][Full Text] [Related]
2. Dendritic cells in Barrett's esophagus carcinogenesis: an inadequate microenvironment for antitumor immunity?
Somja J; Demoulin S; Roncarati P; Herfs M; Bletard N; Delvenne P; Hubert P
Am J Pathol; 2013 Jun; 182(6):2168-79. PubMed ID: 23619476
[TBL] [Abstract][Full Text] [Related]
3. Immune microenvironment in Barrett's esophagus adjacent to esophageal adenocarcinoma: possible influence of adjacent mucosa on cancer development and progression.
Gokon Y; Fujishima F; Taniyama Y; Ishida H; Yamagata T; Sawai T; Uzuki M; Ichikawa H; Itakura Y; Takahashi K; Yajima N; Hagiwara M; Nishida A; Ozawa Y; Sakuma T; Kanba R; Sakamoto K; Zuguchi M; Saito M; Kamei T; Sasano H
Virchows Arch; 2020 Dec; 477(6):825-834. PubMed ID: 32533341
[TBL] [Abstract][Full Text] [Related]
4. An ex vivo readout for evaluation of dendritic cell-induced autologous cytotoxic T lymphocyte responses against esophageal cancer.
Milano F; Rygiel AM; Buttar N; Bergman JJ; Sondermeijer C; van Baal JW; ten Brinke A; Kapsenberg M; van Ham SM; Peppelenbosch MP; Krishnadath KK
Cancer Immunol Immunother; 2007 Dec; 56(12):1967-77. PubMed ID: 17564704
[TBL] [Abstract][Full Text] [Related]
5. Immune determinants of Barrett's progression to esophageal adenocarcinoma.
Lagisetty KH; McEwen DP; Nancarrow DJ; Schiebel JG; Ferrer-Torres D; Ray D; Frankel TL; Lin J; Chang AC; Kresty LA; Beer DG
JCI Insight; 2021 Jan; 6(1):. PubMed ID: 33290281
[TBL] [Abstract][Full Text] [Related]
6. Efficient induction of anti-tumor immune response in esophageal squamous cell carcinoma via dendritic cells expressing MAGE-A3 and CALR antigens.
Liu X; Song N; Liu Y; Liu Y; Li J; Ding J; Tong Z
Cell Immunol; 2015 Jun; 295(2):77-82. PubMed ID: 25863743
[TBL] [Abstract][Full Text] [Related]
7. Novel therapeutic strategies for treating esophageal adenocarcinoma: the potential of dendritic cell immunotherapy and combinatorial regimens.
Milano F; Krishnadath KK
Hum Immunol; 2008 Oct; 69(10):614-24. PubMed ID: 18703104
[TBL] [Abstract][Full Text] [Related]
8. Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells.
Nair SK; Morse M; Boczkowski D; Cumming RI; Vasovic L; Gilboa E; Lyerly HK
Ann Surg; 2002 Apr; 235(4):540-9. PubMed ID: 11923611
[TBL] [Abstract][Full Text] [Related]
9. Comparative Multi-Epitope-Ligand-Cartography reveals essential immunological alterations in Barrett's metaplasia and esophageal adenocarcinoma.
Berndt U; Philipsen L; Bartsch S; Hu Y; Röcken C; Bertram W; Hämmerle M; Rösch T; Sturm A
Mol Cancer; 2010 Jul; 9():177. PubMed ID: 20604962
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells.
Yasuda T; Kamigaki T; Nakamura T; Imanishi T; Hayashi S; Kawasaki K; Takase S; Ajiki T; Kuroda Y
Oncol Rep; 2006 Dec; 16(6):1317-24. PubMed ID: 17089056
[TBL] [Abstract][Full Text] [Related]
11. Expression profiles of cancer stem cell markers: CD133, CD44, Musashi-1 and EpCAM in the cardiac mucosa-Barrett's esophagus-early esophageal adenocarcinoma-advanced esophageal adenocarcinoma sequence.
Mokrowiecka A; Veits L; Falkeis C; Musial J; Kordek R; Lochowski M; Kozak J; Wierzchniewska-Lawska A; Vieth M; Malecka-Panas E
Pathol Res Pract; 2017 Mar; 213(3):205-209. PubMed ID: 28216140
[TBL] [Abstract][Full Text] [Related]
12. Expression of the putative stem cell marker Musashi-1 in Barrett's esophagus and esophageal adenocarcinoma.
Bobryshev YV; Freeman AK; Botelho NK; Tran D; Levert-Mignon AJ; Lord RV
Dis Esophagus; 2010 Sep; 23(7):580-9. PubMed ID: 20459440
[TBL] [Abstract][Full Text] [Related]
13. Dendritic Cells and Cancer Immunity.
Gardner A; Ruffell B
Trends Immunol; 2016 Dec; 37(12):855-865. PubMed ID: 27793569
[TBL] [Abstract][Full Text] [Related]
14. A study of the immune infiltrate and patient outcomes in esophageal cancer.
Conroy MJ; Kennedy SA; Doyle SL; Hayes B; Kavanagh M; van der Stok EP; O'Sullivan K; Cathcart MC; Reynolds JV; Lysaght J
Carcinogenesis; 2021 Apr; 42(3):395-404. PubMed ID: 32940666
[TBL] [Abstract][Full Text] [Related]
15. In vivo induction of dendritic cell-mediated cytotoxicity against allogeneic pancreatic carcinoma cells.
Stift A; Friedl J; Dubsky P; Bachleitner-Hofmann T; Benkoe T; Brostjan C; Jakesz R; Gnant M
Int J Oncol; 2003 Mar; 22(3):651-6. PubMed ID: 12579320
[TBL] [Abstract][Full Text] [Related]
16. Immune responses in patients with esophageal cancer treated with SART1 peptide-pulsed dendritic cell vaccine.
Narita M; Kanda T; Abe T; Uchiyama T; Iwafuchi M; Zheng Z; Liu A; Kaifu T; Kosugi S; Minagawa M; Itoh K; Takahashi M
Int J Oncol; 2015 Apr; 46(4):1699-709. PubMed ID: 25625346
[TBL] [Abstract][Full Text] [Related]
17. [The killing effect of cytotoxic T lymphocytes on esophageal adenocarcinoma cells mediated by gp96-peptide complexes].
Ma LP; Pan XY; Li N; Liu YJ; Chen XX
Beijing Da Xue Xue Bao Yi Xue Ban; 2004 Oct; 36(5):525-8. PubMed ID: 15489936
[TBL] [Abstract][Full Text] [Related]
18. Eliciting cytotoxic T lymphocytes against human laryngeal cancer-derived antigens: evaluation of dendritic cells pulsed with a heat-treated tumor lysate and other antigen-loading strategies for dendritic-cell-based vaccination.
Wei FQ; Sun W; Wong TS; Gao W; Wen YH; Wei JW; Wei Y; Wen WP
J Exp Clin Cancer Res; 2016 Jan; 35():18. PubMed ID: 26795730
[TBL] [Abstract][Full Text] [Related]
19. Generation of populations of antigen-specific cytotoxic T cells using DCs transfected with DNA construct encoding HER2/neu tumor antigen epitopes.
Kuznetsova M; Lopatnikova J; Khantakova J; Maksyutov R; Maksyutov A; Sennikov S
BMC Immunol; 2017 Jun; 18(1):31. PubMed ID: 28633645
[TBL] [Abstract][Full Text] [Related]
20. Activated dendritic cells delivered in tissue compatible biomatrices induce in-situ anti-tumor CTL responses leading to tumor regression.
Verma V; Kim Y; Lee MC; Lee JT; Cho S; Park IK; Min JJ; Lee JJ; Lee SE; Rhee JH
Oncotarget; 2016 Jun; 7(26):39894-39906. PubMed ID: 27223090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
